Intermittent nesiritide therapy in outpatients with chronic heart failure
Heart failure (HF) continues to be a significant health problem in the United States. Nearly 550,000 people are diagnosed annually with this condition, and HF is responsible for over 1 million hospitalizations per year.1,2 Despite advances in pharmacologic therapy, a small percentage of patients wit...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | article |
| منشور في: |
2005
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/3932 https://doi.org/10.1093/ajhp/62.2.196 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/62/2/196/5135612 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | Heart failure (HF) continues to be a significant health problem in the United States. Nearly 550,000 people are diagnosed annually with this condition, and HF is responsible for over 1 million hospitalizations per year.1,2 Despite advances in pharmacologic therapy, a small percentage of patients with severe HF remain refractory to maximum medical therapy. In addition, these patients have high mortality rates, a poor quality of life, and frequent hospitalizations with elevated health care costs. For this subset of patients, some centers in the United States continue to use periodic ino-tropic therapy on an inpatient or outpatient basis under the rationale of reducing symptoms, hospitalizations, and medical costs, even at the risk of increased mortality. Nesiritide, a human B-type natriuretic peptide, is the first of a new class of agents for the treatment of decompensated HF. In... |
|---|